Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Antivir Ther. 2014 Oct 27;20(3):307–315. doi: 10.3851/IMP2912

Figure 1.

Figure 1

Figure 1

Figure 1

Efficacy outcomes by first-year vRNA response category: (A) % of patients with vRNA <50 copies/mL, (B) % of patients with vRNA <400 copies/mL, and (C) change from baseline in CD4 cell count.